The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancer
Maurie Markman
Correspondence The University of Texas, MD Anderson Cancer Center, (Mail Box #121), 1515 Holcombe Boulevard, Houston, TX 77030, USA
Email mmarkman@mdanderson.org
This article has no abstract so we have provided the first paragraph of the full text.
The serum level of the CA125 antigen has been documented as a useful marker for evaluating the status of disease in individual patients with EOC.1, 2 A rising antigen level, confirmed on repeat laboratory testing, provides very strong evidence for progression of the disease process. Conversely, a declining value is a reliable indicator of a biological response to a particular therapeutic program. Further, formal criteria have been developed and accepted by the international clinical gynecologic cancer research community, for the employment of specific changes in the CA125 antigen level as objective measures of clinical disease progression in studies of EOC.3
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.